BVX — Bivictrix Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- £9.49m
- £8.00m
2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS |
Standards: | — | IFRS | IFRS |
Status: | Final | Final | Final |
Net Income/Starting Line | -0.49 | -2.53 | -2.97 |
Depreciation | |||
Non-Cash Items | 0.004 | 0.865 | 0.123 |
Other Non-Cash Items | |||
Changes in Working Capital | 0.32 | -0.164 | 0.3 |
Change in Accounts Receivable | |||
Change in Accounts Payable | |||
Change in Payable / Accrued Expenses | |||
Other Operating Cash Flow | |||
Cash from Operating Activities | -0.165 | -1.78 | -2.4 |
Capital Expenditures | -0.063 | -0.046 | -0.389 |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | — | — | 0.01 |
Sale of Fixed Assets | |||
Cash from Investing Activities | -0.063 | -0.046 | -0.379 |
Financing Cash Flow Items | -0.018 | -0.437 | 0 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0.961 | 7.03 | 0 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 0.733 | 5.2 | -2.78 |